# An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury

> **NCT02063295** · PHASE2 · COMPLETED · sponsor: **Zafgen, Inc.** · enrollment: 14 (actual)

## Conditions studied

- Obesity
- Over-weight
- Hypothalamic Injury
- Craniopharyngioma

## Interventions

- **DRUG:** ZGN-440 sterile diluent
- **DRUG:** ZGN-440 for injectable suspension

## Key facts

- **NCT ID:** NCT02063295
- **Lead sponsor:** Zafgen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2016-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02063295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02063295, "An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02063295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*